|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-5-19
|
|
pubmed:abstractText |
Currently, the optimal boosting dose for saquinavir is unknown. Therefore, we evaluated the pharmacokinetics profiles in a cross over setting comparing saquinavir/ritonavir 1500/50 mg (plus NRTI backbone) to saquinavir/ritonavir 1500/100 mg in the same HIV-infected, Thai individuals. The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1473-5571
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1176-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19451794-Adult,
pubmed-meshheading:19451794-Anti-HIV Agents,
pubmed-meshheading:19451794-Cross-Over Studies,
pubmed-meshheading:19451794-Dose-Response Relationship, Drug,
pubmed-meshheading:19451794-Drug Administration Schedule,
pubmed-meshheading:19451794-Female,
pubmed-meshheading:19451794-HIV Infections,
pubmed-meshheading:19451794-HIV-1,
pubmed-meshheading:19451794-Humans,
pubmed-meshheading:19451794-Male,
pubmed-meshheading:19451794-Middle Aged,
pubmed-meshheading:19451794-Ritonavir,
pubmed-meshheading:19451794-Saquinavir
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals.
|
|
pubmed:affiliation |
The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand. jasper.v@hivnat.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
